RESUMO
CLINICAL CASE: Our patient was a 37-year-old male with palpebral mycosis fungoides, the most common T-cell cutaneous lymphoma. He had been treated previously with topical corticosteroids. We treated him with Imiquimod cream (5%) three times a week. DISCUSSION: A clinical improvement was obtained with this drug, so we believe immuno-modulating agents need to be considered in the treatment of palpebral mycosis fungoides, especially because of its capacity of being a reflection of leukaemia.
Assuntos
Aminoquinolinas/uso terapêutico , Antineoplásicos/uso terapêutico , Neoplasias Palpebrais/tratamento farmacológico , Micose Fungoide/tratamento farmacológico , Neoplasias Cutâneas/patologia , Adulto , Neoplasias Palpebrais/patologia , Pálpebras/patologia , Pálpebras/cirurgia , Humanos , Imiquimode , Masculino , Micose Fungoide/patologia , Procedimentos Cirúrgicos Oftalmológicos , Neoplasias Cutâneas/tratamento farmacológico , Resultado do TratamentoRESUMO
Caso clínico: Presentamos el caso de un varón de37 años de edad que presentaba una micosis fungoide,el más frecuente de los linfomas T cutáneos,con localización exclusivamente palpebral quehabía sido tratado previamente con corticoides tópicos.Se instauró un tratamiento con Imiquimod al5% en crema tres veces semanales.Discusión: Con el uso de este medicamento, seconsiguió una gran mejoría clínica del paciente, porlo que consideramos muy importante tener en cuentaeste inmunomodulador para el tratamiento deesta enfermedad, de importancia por su capacidadde leucemización
Clinical case: Our patient was a 37-year-old male with palpebral mycosis fungoides, the most common T-cell cutaneous lymphoma. He had been treated previously with topical corticosteroids. We treated him with Imiquimod cream (5%) three times a week. Discussion: A clinical improvement was obtained with this drug, so we believe immuno-modulating agents need to be considered in the treatment of palpebral mycosis fungoides, especially because of its capacity of being a reflection of leukaemia
